Asthma Medicine

AstraZeneca asthma drug more effective than steroids during attacks: Study

The researchers found that Fasenra can be more effective than the oral corticosteroid prednisolone when injected during an attack, also called an exacerbation, which can involve symptoms such

World Asthma Day 2024: All you need to know about this long-term disorder

Asthma is a persistent long-term lung disorder. World Asthma Day is observed every year to bring issues to light about the disorder and how we can make lives more easier for asthma patients

AstraZeneca, Mankind Pharma partner for distribution of asthma medication

Mankind Pharma, a pharmaceutical company in India, boasts a vast distribution network with over 16,000 field personnel and 13,000 stockists

AstraZeneca, Mankind Pharma sign pact to distribute asthma medicine

AstraZeneca Pharma India Ltd and Mankind Pharma Ltd on Monday said they have entered into an agreement for exclusive distribution of the Symbicort brand, an asthma medicine, in India. Symbicort is owned by AstraZeneca, which will retain the intellectual property rights and will continue to be the marketing authorisation holder (MAH) and import license after the agreement, a joint statement shared on BSE by AstraZeneca Pharma India said. "The partnership with Mankind Pharma presents an opportunity to accelerate access and maximise the potential of our asthma drug as well as the turbuhaler which is a simple device, efficient in consistently delivering a higher proportion of respirable particles than the other devices," AstraZeneca India Managing Director and Country President Sanjeev Panchal said. Mankind Pharma has a distribution network, including close to 16,000 field forces and more than 13,000 stockists, across India providing access to quality pharmaceuticals across the country,

World Asthma Day 2023: History, importance, theme, Celebration, Facts

As we mark World Asthma Day in 2023, it's crucial to know that asthma is a common non-transferable illness that influences people around the world

Lupin launches fixed-dose triple drug combination to manage asthma

Pharmaceuticals firm Lupin Ltd on Thursday said it has launched a fixed-dose triple drug combination of Indacaterol, Glycopyrronium and Mometasone for managing asthma. The product launched under the brand name DIFIZMA is being offered as a dry powder inhalation, the company said in a regulatory filing. "DIFIZMA is the only FDC (fixed-dose combination) that has been approved by the Drug Controller General of India (DCGI) for the treatment of inadequately controlled asthma," it said. The product will help in the management of inadequately controlled asthma by improving lung function, providing better symptom control and reducing exacerbations. The drug will be available in one strength with a fixed-dose to be taken once daily, the company added. Lupin India Region Formulations President Rajeev Sibal claimed that DIFIZMA is a first-of-its-kind novel combination product available in India. It is aimed at catering to the unmet need of patients with inadequately controlled asthma and al

Glenmark Pharma launches first FDC drug Indamet for asthma patients

Glenmark Pharmaceuticals on Thursday said it has launched a novel fixed-dose combination (FDC) drug in the country for patients with uncontrolled asthma. The Mumbai-based drug major has launched - Indacaterol + Mometasone FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg and 320 mcg to be taken once daily. "Respiratory is a key focus area for Glenmark, and the company leads from the front in providing access to the latest treatment options to patients. "We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India, offering an affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma," Glenmark Pharmaceuticals Group Vice President & Head (India Formulations) Alok Malik said in a statement. The drug maker is the first company in India to market the FDC of .

AstraZeneca's Fasenra gets regulatory nod for asthma treatment

AstraZeneca India has received marketing authorisation from the Drugs Controller General of India (DCGI) for use of Fasenra

Asthma drug may cut Parkinson's risk by half

Shivering, stiff arms and legs and poor coordination are typical symptoms of Parkinson's